SCHEMBL4517264

SCHEMBL4517264

CC(C(=O)O)C1CC(c2ccc(C(F)(F)F)cc2)N(Cc2ccccc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.42
▸ PSEN1 P49768 3/20 0.42
▸ PSEN2 P49810 3/20 0.42
▸ APH1B Q8WW43 3/20 0.42
▸ NCSTN Q92542 3/20 0.42
▸ APH1A Q96BI3 3/20 0.42
▸ PSENEN Q9NZ42 3/20 0.42
▸ NR1H2 P55055 2/20 0.41
▸ NR1H3 Q13133 2/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ EPAS1 Q99814 1/20 0.41
▸ MDM2 Q00987 1/20 0.41
▸ SIGMAR1 Q99720 3/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ DRD2 P14416 1/20 0.39
▸ DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4517269 1.00 LMNA (0.42) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL4495877 0.96 PSEN1 (0.43) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL4512703 0.89 KCNH2 (0.44) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL4512700 0.89 KCNH2 (0.44) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL4506817 0.83 FFAR1 (0.45) —
SCHEMBL4506818 0.83 FFAR1 (0.45) —
SCHEMBL2860479 0.79 PSEN1 (0.50) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL2860484 0.79 PSEN1 (0.50) LMNAPSEN1PSEN2APH1BNCSTN
SCHEMBL28824755 0.78 LMNA (0.51) LMNANR1H2NR1H3SIGMAR1MAPT
SCHEMBL29617606 0.78 L3MBTL1 (0.46) HIF1AEPAS1MDM2SIGMAR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638629-B2 Piperidines and related compounds for treatment of alzheimer's disease Merck Sharp & Dohme Ltd, (GB) 2009-12-29 — — US disclosed
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021043-A1 Piperidines and Related Compounds for Treatment of Alzheimer's Disease PSEN1, PSEN2, APP LMNA 1344/4885PSEN1 1/4885PSEN2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback